Abstract. The aim of the present study was to investigate the effects of betulinic acid (BetA) on the expression and distribution pattern of nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d), an indirect indicator of nitric oxide (NO) synthase in the thymus and spleen of mice. Mice were randomly assigned to four main groups (n=48 per group): Experimental group (BetA), positive control group (goniothalamin), vehicle control group (dimethyl sulfoxide) and control group (without vehicle). Each group was further divided into three equal subgroups according to the treatment length (4, 8 and 12 days). BetA treatment induced the expression of NADPH-d activity in the thymus and spleen without any significant changes in the morphology of the organs. Furthermore, the expression pattern of NADPH-d in BetA-treated animals was significantly increased compared with that in the control animals. NADPH-d expression in the thymus and spleen suggests that NO signaling may be a potential mechanism underlying the BetA-induced immunomodulation in these organs. These findings are of direct clinical relevance and may contribute to the further development of BetA as a therapeutic drug.

Introduction

Numerous diseases, including cancer require modulation in the immune system for disease management and care (1). Under the circumstance of weakened immune responsiveness, the host protection machinery has to be activated to provide an alternative to conventional chemotherapy (2). Potential immunomodulatory agents (3,4) have been identified based on the observed therapeutic effects of phytochemicals isolated from various plants (5-7), and segregates of microorganisms and mammalian proteins, including immune mediators and certain synthetic chemicals (8).

The triterpene alcohol, betulin and its equivalent carboxylic acid, betulinic acid (BetA; Fig. 1) are isolated from betula birch bark (9), which has been used for various medicinal purposes in many countries (10). BetA is a pentacyclic lupane-type triterpenoid of which a wide range of biological properties have been shown against cancer, inflammation, malaria, and helmintic and viral activities (11-14). Among these, the anticancer and cytotoxic activities of BetA have received significant attention (15,16). Selective cytotoxicity has been demonstrated in multiple tumor cell lines (15-19) without effect in normal cells, including dermal fibroblasts and peripheral blood lymphocytes (20 -22). Furthermore, no systemic toxic effects have been observed in rodents (23).

Despite a lack of toxicity, the poor potency of BetA hinders its clinical development. Mullauer et al (23) cautioned that existing in vivo data are insufficient to support that BetA does not cause an effect on healthy cells. Furthermore, in contrast to previous findings, a recent study by Heiss et al (24) reported that 10 µM BetA induces changes in normal cellular metabolism. The study by Heiss et al (24) raised concerns regarding the clinical application of BetA and prompted us to investigate whether BetA may cause any major effects on healthy cells in the immune organs of mice.

Nitric oxide (NO) is a free radical and ubiquitous signaling molecule (25,26) present in immune and endocrine tissues, among others (27-29) and a well-known mediator in numerous therapeutic and immunomodulatory functions, indicating a regulatory function of NO in primary and secondary immune organs. There are three isoforms of NO synthases (NOSs),
which are neuronal (nNOS), inducible (iNOS) and endothelial (eNOS), and they are responsible for the synthesis of NO from the amino acid, l-arginine (30). Previous studies have demonstrated that all three isoforms express enzymatic activity of NADPH-d (31,32), and indicated the expression pattern of NADPH-d is an indirect indication of the presence of NOS and NO (30,33). Therefore NADPH-d activity has been used as a marker for NOS.

Therefore, the current study was performed to determine whether 10 µM BetA modulates NO production or induces changes in healthy spleen and thymus cells in mice, and to investigate the possible functions of BetA in these organs. A histochemical analysis of NADPH-d, a marker for NOS, was also performed (34).

Materials and methods

Animals and reagents. Animal experiments were conducted in accordance with the National University of Malaysia (UKM; Kuala Lumpur, Malaysia) animal ethics guidelines and regulations laid out by the Institutional Animal Ethics Committee (UKMAEC; FF/2016/ALI/20‑MAY/685‑JUNE‑2016). Six-week-old, female BALB/c mice procured from the institutional animal holding facility (n=196), were maintained (2-3 animals/cage) under pathogen-free conditions and a 12-h light/dark cycle, with access to commercial pellets and distilled water. BetA (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) served as a test drug, goniothalamin (GTN; provided by Dr Ibrahim Jantan, Faculty of Pharmacy, UKM) served as a positive control drug, and dimethyl sulfoxide (DMSO; Merck KGaA) served as a vehicle.

Animal treatment and sample collection. Animals were randomly divided into four main groups as follows: Experimental group (10 µM BetA; n=48), a positive control group (50 µM GTN; n=48), a negative control group (0.05% DMSO; n=48) and a normal standard control group (n=48). Each main group of animals was further divided into three equal subgroups (n=6 per group) corresponding to the treatment period (4, 8 and 12 days). Chloral hydrate (10%; i.p.) was administered to anesthetize the animals, subsequently animals were fixed using 4% paraformaldehyde and a transcardiac perfusion method described by Syed et al (27). The fixed tissue blocks were maintained in the same fixative solution for 24 h, washed twice in phosphate buffer (PB) and cryoprotection in 30% sucrose. Tissue blocks were maintained in the same fixative solution (34).

Results

NADPH-d expression in the thymus. Although the control group (DMSO-treated vehicle) received no drug treatment, weak or faint NADPH-d staining was observed in the cortex and medulla region of the thymus (Fig. 2A-C), whereas in the positive-control group (GTN), the capsule and cortex region demonstrated moderate NADPH-d expression 4 days after the GTN injection, which continuously increased at the eighth and twelfth day of treatment (Fig. 2D-F). This indicates that GTN induces time-dependent expression of NADPH-d in the thymus. However, the NADPH-d distribution was initially similar to that in the control group after day 4, and subsequently the distribution spread to the whole lobule on the eighth and twelfth day of treatment.

Similarly, a gradual increase of NADPH-d distribution (P<0.001) was observed in the BetA treatment group and its activity increased along with longer BetA exposure (Fig. 2G-I). However, the thymus displayed only slight to moderate NADPH-d staining after 4 days (Fig. 2G), 8 days (Fig. 2H) and 12 days of BetA treatment (Fig. 2I), in the cortex and the medullary region. The interlobular septum extends from the capsule into the thymus, subdividing the thymus into interconnecting lobules, which are of varying size and orientation. The expression pattern of NADPH-d spread to a wider area at the medullary region across the septum 8 days after BetA treatment, demonstrating higher NADPH-d activity. As the septum is the site where blood vasculatures in the thymus are oriented, staining in this region (Fig. 2C and G) supports that NO has a role in vascular physiology. The graph (Fig. 2J) demonstrates the intensity (OD) per staining area (cm²) of the thymus tissue sections after 4, 8 and 12 days of treatment. Increased NADPH-d expression indicates that the effect of BetA on the thymus depends on exposure time.

NADPH-d expression in the spleen. Compared with that in the control group (Fig. 3A-C), the spleen of the GTN (Fig. 3D-F) and BetA groups (Fig. 3G-I) demonstrated a particularly
strong NADPH-d reaction, with increased expression levels in the cortex and medullary regions (Fig. 3D-I), as well as in the vasculature (Fig. 3C, F and I), which increased with longer exposure times. The spleen is enclosed by a fibro elastic outer connective tissue, the capsule, and composed of white and red pulp, forming two functionally and morphologically different units. The NADPH-d staining (brown precipitate) was more widely present in the red pulp than in the white pulp area. The red pulp region is comprised of various cells, including sinusoids (35). The graph (Fig. 3J) demonstrates the intensity (OD) per staining area (cm²) of the spleen tissue sections after 4, 8 and 12 days of treatment.

Morphological changes. No phenotypical appearance or significant morphological changes were observed in either the GTN- or the BetA-treated thymus and spleen.

Discussion

The present study demonstrated positive NADPH-d staining in the thymus and in the spleen of non-immunized GTN and BetA-treated mice. However, its expression and distribution pattern varied with these agents throughout the treatment period. Although no morphological or phenotypical changes were evident in these organs, the NADPH-d activity was more prominent in the spleen than in the thymus. The red pulp region of the spleen strongly expressed NADPH-d, whereas only a moderate reactivity was observed in the white pulp region. Although NADPH-d expression was detected after 4 days, a significant increase in expression was observed after 8 days of BetA treatment, indicating the contribution of NADPH-d in spleen NO generation during the entire treatment period. Similarly, a steady increase in NADPH-d activity in the thymus beginning from day 4 may specify an interactive outcome of NO on the thymus vascular and medulla regions, which may be involved in immune modulation (33,36-37). Although the function of NO in the thymus and spleen has not been demonstrated, the findings of the current study indicate that there is an association between the immunological effects induced by BetA. The major effect of BetA-induced NO appears to be involved in maintenance of the immune system (38-40) and the current results support other reports in which the presence of NO was demonstrated in the immune system (33,41).

It has been demonstrated that the expression of NOS and production of NO are characteristic of cells involved in immune responses (33,36,42). Although NO is less active in cells from normal mice (43), a spleen cell subpopulation produces enough NO during an in vitro immune response to completely prevent multiplication of T cells (44,45). Similarly, previous studies have demonstrated that a wide range of potential immunomodulatory functions may be expected for NO in the thymus, including the following: Induction of tolerance, restriction of major histocompatibility complex, lymphocyte trafficking and regulation of thymic endocrine output (33,36,37,42). Furthermore, if there are effects or changes in the cells due to BetA treatment, it is assumed that NO may be produced to perform its regulatory roles in the cells of these immune organs.

Betulin and BetA trigger and modify cytokine production in human whole blood cell cultures (46). To support this hypothesis, previous studies have reported that BetA augments mouse immune function, including cellular and humoral immunity, and activity of phagocytic macrophages (39,47). BetA was identified as a modulatory agent of cytokine production by T helper cells (Th1/Th2) and other immune cells in animals. Consistently, the results of numerous studies indicated that BetA may be useful for modulation of the immune system (40,48-51). Furthermore, various bioactive materials derived from other plants exhibit immunomodulatory abilities (52-55).

In addition, NO is recognized to act as a vasodilator following its release from endothelial cells (56-58), including BetA-treated endothelial cells (59-62). This function is mediated by NO inhibitory action on vascular smooth muscles. However, Moncada et al (25) and other studies (63,64) have demonstrated that NO-mediated vasodilation occurs without endothelial cells present, where the NO-positive nitrergic nerves may act directly on smooth muscle cells, leading to vasodilation. Such control by neuronal NO has also been demonstrated in the peripheral nervous system (65,66).

The innervation of NO-positive perivascular nerves has also been demonstrated in many types of vascular tissue (67-69). The distribution of supply of nerves in the thymus are not entirely known; however, previous studies focused on the neural structures contained within the thymus (70,71). The activity of NADPH-d was demonstrated in many parts of the nervous system in mammals (72-74). The present results are consistent with previous findings that NADPH-d-labelled cells are present in the rat thymus (28,30,75). Although the current study observed NADPH-d-stained nerve fibers in
the perivascular area, no NADPH-d neuronal cell body-like structures were observed in either the thymus or the spleen. The moderate distribution of NO-containing nerves traveling along blood vessels may reflect a particularly significant role that neuronal NO may perform in controlling blood flow through the thymus and spleen. The fact that NO-positive nerves and the vascular endothelium may produce NO to influence blood flow has been described in the nervous
system (74), pancreas (76), thyroid (27,29) and various other tissues. This observation indicates that NO participates in neurotransmission in the thymus and spleen. It is important to note that in addition to blood vessels, NO may regulate the secretory activity of immune cells by its generation in these cells (77). Thus, BetA may present a promising biological response modifier and may reinforce the immune response of a host.

In conclusion, the current study demonstrates that BetA treatment induces the expression of NADPH-d activity in the thymus and spleen without causing any significant changes to the morphology of the organs. These findings are of direct clinical relevance and may contribute to the progression of drug discovery. To the best of our knowledge, this is the most significant study describing BetA-induced, NADPH-d-mediated NO signaling, which may be the mechanism underlying BetA-elicited immunomodulation in these organs.

**Acknowledgements**

The present study was partly supported by an internal research grant (grant no. 1437-0195) obtained from the Deanship of Scientific Research University of Tabuk (Tabuk, Saudi Arabia).
References

1. Geetha S, Singh V, Ram MS, Ilavazhagam G, Banerjee PK and Sawhney RC: Immunomodulatory effects of seabuckthorn (Hippophae rhamnoides L.) against chromium (VI) induced immunosuppression. Mol Cell Biochem 278: 101-109, 2005.

2. Aravinandam K and Yang NS: Anti-inflammatory plant natural products for cancer therapy. Planta Med 76: 1103-1117, 2010.

3. Winkler C, Wirleitner B, Schroeschnadel K, Schennach H, Mur E and Fuchs D: In vitro effects of two extracts and two pure alkaloid preparations of Uncaria tomentosa on peripheral blood mononuclear cells. Planta Med 70: 205-210, 2004.

4. Patwardhan B and Gautam M: Botanical immunomods: Scope and opportunities. Drug Discov Today 10: 495-502, 2005.

5. Sreesha T: In-vitro study of cytotoxic activity of flavonoid fraction from the petals of Cassia senna. Int J Ethnomed Herbal Res 1: 52-53, 2013.

6. Nagarathna PKM, Reena K, Srima Reddy and Johnson W: Review on immunomodulation and immunomodulatory activity of some herbal plants. Int J Pharm Sci Res 22: 223-230, 2013.

7. Ibrahim J, Waqas A and Syed Nasir AB: Plant-derived immunomodulators: An insight on their preclinical evaluation and clinical trials. Front Plant Sci 6: 655, 2015.

8. Schepetkin IA and Quinn MT: BTM: Polyphenol polysaccharides: Macrophage immunomodulation and therapeutic potential. Int Immunopharmacol 6: 317-333, 2006.

9. Eizhamer DA and Xu QZ: Betulinic acid: A promising anti-cancer candidate. I Drugs 7: 359-373, 2004.

10. Higa M, Noha N, Yokaryo H, Ogihara K and Yogi S: Three new naphthoquinone derivatives from Diospyros maritima Blume. Chem Pharm Bull (Tokyo) 50: 590-593, 2002.

11. Hanson JR: Pentacyclic triterpenes as promising agents in cancer. Salvador JAR (ed). Nova Science Publishers, Inc, New York, NY, p191, 2010.

12. Santos RC, Salvador JA, Marín S, Cascante M, Moreira JN and Dinis TC: Synthesis and structure-activity relationship study of novel cytotoxic carbamate and N-acetylhydroxycyclic bearing derivatives of betulin and betulinic acid. Bioorg Med Chem 18: 4385-4396, 2010.

13. Zhang DM, Xu HG, Wang L, Li YJ, Sun PH, Wu XM, Wang GJ, Chen WM and Ye WC: Betulinic acid and its derivatives as potential antitumor agents. Med Res Rev 35: 1127-1155, 2015.

14. Ali-Sayed M, Jantam I, Vijayaraghavan K and Bukhari S: Betulinic acid: Recent advances in chemical modifications, effective delivery, and molecular mechanisms of a promising anticancer therapy. Chem Biol Drug Des 87: 517-536, 2016.

15. Alakurtti S, Mäkelä T, Koksimies S and Yli-Kauhalouma J: Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci 29: 1-13, 2006.

16. Csuk R: Betulinic acid and its derivatives: A patent review (2008-2013). Expert Opin Ther Pat 24: 913-923, 2014.

17. Zaro V, Serafini R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C and Formelli F: Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 175: 17-25, 2002.

18. Thurnher D, Turhani D, Pelzmann M, Wannerbacher B, Knerer B, Yi JE, Obminska -Mrukowicz B, Yuan LY and Yuan H: Immunomodulatory effects of betulinic acid from the bark of white birch on mice. J Vet Sci 11: 305-313, 2010.

19. Jine Y, Lis M, Szczypka M and Obminska-Mrukowicz B: Influence of betulinic acid and its derivatives for the induction of inhibitory nitric-oxide synthase induction in RAW 264.7 macrophages. J Biol Chem 276: 47950-47957, 2001.

20. Yi JE, Obminska-Mrukowicz B, Yuan LY and Yuan H: Immunomodulatory effects of betulinic acid from the bark of white birch on mice. J Vet Sci 11: 305-313, 2010.

21. Selzer E, Pentelent E, Wachek C, Schlegel W, Pehamberger H, Janss B and Kodym R: Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J Invest Dermatol 114: 935-940, 2000.

22. Periasamy G, Teketelew G, Gebrelhanos M, Sintayehu B, Gebrehiwot M, Karim A and Geremedhin G: Betulinic acid and its derivatives as anti-cancer agent: A review. Arch Appl Sci Res 6: 4385-4396, 2014.

23. Mullauer FB, Kessler JH and Medema JP: Betulinic acid, a natural compound with potent anticancer effects. Anticancer Drugs 21: 215-227, 2010.
48. Sultana N and Saify ZS: Naturally occurring and synthetic agents as potential anti-inflammatory and immunomodulants. Antimicrob Agents Chemother 11: 3-19, 2012.

49. Wang P, Li Q, Li K, Zhang X, Han Z, Wang J, Gao D and Li J: Betulinic acid exerts immunoregulation and anti-tumor effect on cervical carcinoma (U14) tumor-bearing mice. Pharmazie 67: 733-739, 2012.

50. Dash SK, Chattopadhyay S, Tripathy S, Dash SS, Das B, Mandal D, Mahapatra SK, Bag BG and Roy S: Self-assembled betulinic acid augments immunomodulatory activity associates with IgG response. Biomed Pharmacother 75: 205-217, 2017.

51. Yi J, Zhu R, Wu J, Wu J, Xia W, Zhu L, Jiang W, Xiang S and Tan Z: In vivo protective effect of betulinic acid on dexamethasone induced thymocyte apoptosis by reducing oxidative stress. Pharmacol Rep 68: 95-100, 2016.

52. Kovalenko LP, Balakshin VV, Presnova GA, Christyakov AN, Shipaeva EV, Alekseeva SV and Durnev AD: Immunotoxicity and allergenic properties of betulin-containing birch bark dry extract. Pharm Chem J 41: 17-19, 2007.

53. Naithani R, Huma LC, Moriarty RM, McCormick DL and Mehta RG: Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 15: 1044-1071, 2008.

54. Paszkiewicz M, Budzińska A, Różalska B and Sadowska B: The immunomodulatory role of plant polyphenols. Postepy Hig Med Dosw (Online) 66: 637-636, 2012 (In Polish).

55. Mathew NS and Negi PS: Traditional uses, phytochemistry and pharmacology of wild Banana (Musa acuminate Colla): A review. J Ethnopharmacol 196: 124-140, 2017.

56. Schmidt A, Bilgasem S, Lorkowski S, Vischer P, Völker W, Breithardt G, Siegel G and Buddecke E: Multiple nitric oxide synthase isoforms as determinants of health and disease. Free Radic Biol Med 49: 307-316, 2010.

57. Downing JE: Multiple nitric oxide synthase systems in adult rat thymus revealed using NADPH diaphorase histochemistry. Immunology 82: 659-664, 1994.

58. Steinkamp-Fenske K, Bollinger L, Xu H, Yao O, Horke S, Förstermann U and Li H: Reciprocal regulation of endothelial nitric-oxide synthase and NADPH oxidase by betulinic acid in human endothelial cells. J Pharmaco Exp Ther 322: 836-842, 2007.

59. Chen MF, Huang YC, Long C, Yang HI, Lee HC, Chen PY, Hoffer BJ and Lee TJ: Bimodal effects of fluoxetine on cerebral nitrogic neurogenic vasodilation in porcine large cerebral arteries. Neuropharmacology 62: 1651-1658, 2012.

60. Lies B, Beck K, Keppler J, Saur D, Groneberg D andFribe A: Nitricergic signalling via interstitial cells of Cajal regulates motor activity in murine colon. J Physiol 593: 4589-4601, 2015.

61. Wensisch S and Arnhold S: NADPH-diaphorase activity and NO synthase expression in the olfactory epithelium of the bovine. Anat Histol Embryol 39: 201-206, 2010.

62. Şelaru M, Rusu MC and Jianu AM: Expression of nNOS in the human larynx. Anat Sci Int 90: 327-330, 2015.

63. Chen MF, Huang YC, Long C, Yang HI, Lee HC, Chen PY, Hoffer BJ and Lee TJ: Bimodal effects of fluoxetine on cerebral nitrogic neurogenic vasodilation in porcine large cerebral arteries. Neuropharmacology 62: 1651-1658, 2012.

64. Lies B, Beck K, Keppler J, Saur D, Groneberg D and Fribe A: Nitricergic signalling via interstitial cells of Cajal regulates motor activity in murine colon. J Physiol 593: 4589-4601, 2015.

65. Wensisch S and Arnhold S: NADPH-diaphorase activity and NO synthase expression in the olfactory epithelium of the bovine. Anat Histol Embryol 39: 201-206, 2010.

66. Knipping S, Holzhausen HJ, Berghaus A, Blochung M and Riederer A: Ultrastructural detection of nitric oxide in human nasal mucosa. Otalaryngol Head Neck Surg 132: 620-625, 2005.

67. Koyama T, Hatanaka Y, Jin X, Yokomizo A, Fujiwara H, Goda M, Hobara N, Yamami Y, Kitamura Y and Kawasaki H: Altered function of nitric nerves inhibiting sympathetic neurotransmission in mesenteric vascular beds of renovascular hypertensive rats. Hypertens Res 33: 485-491, 2010.

68. Shimada S, Todoki K, Omori Y, Toyama T, Matsuo M, Wada-Takahashi S, Takahashi SS and Lee MC: Contribution of nitrogic nerve in canine gingival reactive hyperemia. J Clin Biochem Nutr 56: 98-104, 2015.

69. Mignini F, Sabbatini M, D’Andrea V and Cavallotti C: Intrinsic innervation and dopaminergic markers after experimental denervation in rat thymus. Eur J Histochim 54: e17, 2010.

70. Liu C, Yang Y, Hu X, Li JM, Zhang XM, Cai Y, Li Z and Yan XX: Ontogenesis of NADPH-diaphorase positive neurons in guinea pig neocortex. Front Neuroanat 9: 11, 2015.

71. Jung J, Na C and Huh Y: Alterations in nitric oxide synthase in the aged CNS. Oxid Med Cell Longev 2012: 718976, 2012.

72. Cossenza M, Sodocato R, Portugal CC, Domith IC, Gladulich LF, Encarnação TG, Calaza KC, Mendoça HR, Campello-Costa P and Paes-de-Carvalho R: Nitric oxide in the nervous system: Biochemical, developmental, and neurobiological aspects. Vitam Horm 79: 79-125, 2014.

73. Downing JE: Multiple nitric oxide synthase systems in adult rat thymus revealed using NADPH diaphorase histochemistry. Immunology 82: 659-664, 1994.

74. Villanueva C and Giuli ci C: Subcellular and cellular locations of nitric-oxide synthase isozymes as determinants of health and disease. Free Radic Biol Med 49: 307-316, 2010.

75. Bogdan C: Nitric oxide synthase in innate and adaptive immunity: An update. Trends Immunol 36: 161-178, 2015.